Osaka Prefectural Hospital Organization

Dna Chip Research Inc.

Japan Science and Technology Corporation

Taisho Pharmaceutical Co., Ltd.

Research Development Corporation of Japan

Dainippon Sumitomo Pharma Co., Ltd.

Koken Company, Limited

Japan As Represented by President of National Cancer Center

National Cancer Center

Sumitomo Dainippon Pharma Co., Ltd.

Kikuya Kato

Ryo Matoba

Yoji Kukita

Takahiro Ochiya

Kimi Honma

Yasuji Ueda

The object of the invention is to provide a method for counting the number of nucleic acid molecules in a mixture of a plurality of nucleic acid molecules more highly accurately. This is a method for highly accurately counting the number of nucleic acid molecules by detecting the read errors that occur when determining a nucleic acid base sequence, wherein the method has: a step for adding a barcode-sequence-generating oligonucleotide to a mixture of a plurality of nucleic acid molecules, thereby linking barcode sequences unique to the nucleic acid molecules to the base sequences constituting each of the nucleic acid molecules; a step for determining the base sequences of the nucleic acid molecules to which the barcode sequences have been linked; a step for detecting read errors in the barcode sequences for which the base sequences have been determined; and a step for calculating the proportion of barcode sequences free of read errors to all of the barcode sequences for which the base sequences have been determined, on the basis of the number of reads of the barcode sequences for which the base sequences have been determined, the abovementioned barcode-sequence-generating oligonucleotide comprising a maximum of five bases, and the number of barcode sequences free of read errors indicating the number of nucleic acid molecules in the mixture.

Method for counting number of nucleic acid molecules

The present invention uses an RPN2 gene expression inhibitor as a cancer cell growth inhibitor, which further includes a drug showing an anti-cancer action if desired, and is administered in combination with atelocollagen if desired. In addition, the present invention is an anti-cancer agent including such cancer cell growth inhibitor.

Method of treating cancer with an RPN2 gene expression inhibitor

The present invention relates to a method for quantitatively determining the expression of a gene, comprising providing at least two types of samples each containing a cDNA coding for the gene, adding a different adaptor to each of the cDNAs contained in the samples, mixing equal amounts of the samples each containing the adaptor-tagged cDNA, amplifying the resultant cDNAs and calculating an amount ratio between the amplified products.

Method for quantitatively determining the expression of a gene

This invention relates to a method for classifying (indexing) cDNA which has been reverse-transcribed from tissue- or cell-derived RNA, or DNA in a short period without duplication by using class-IIS restriction enzymes or a combination of a class-IIS and a class-II restriction enzymes. According to this invention, it is possible to analyse and diagnose variations such as tumors easily, correctly and promptly by comparing the analyzed pattern of genes expressed in a cell or tissue sample with the analyzed pattern of normal genes. This method is also applicable to the search and isolation of genes of physiologically active substances that are potential pharmaceuticals or causative genes of hereditary diseases, as well as the isolation of those genes that are useful for improving agricultural products.

Molecular indexing for expressed gene analysis

Growing community of inventors

Osaka, Japan

Kikuya Kato